科技圈🎗在花频道📮 | Telegram Webview: TestFlightCN/31945 -

科技圈🎗在花频道📮

过敏性鼻炎治疗研究取得新进展

2025年4月4日，首都医科大学附属北京同仁医院张罗教授团队在国际顶级期刊《自然·医学》（Nature Medicine）发表突破性研究成果——《司普奇拜单抗治疗中重度季节性过敏性鼻炎：一项随机3期试验》（Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial）。
这是全球范围内首次报告基于IL-4Rα靶点的生物制剂治疗季节性过敏性鼻炎的研究成果，亦是中国科学家在过敏性鼻炎领域取得的引领世界的创新性新成果。研究结果显示，司普奇拜单抗能够快速、强效控制患者的鼻部症状，持续显著缓解患者眼部过敏症状，极大提升患者生活质量，且安全性良好。

Nature Medicine

📮投稿 ☘️频道 🌸聊天

www.tg-me.com/ms/在花软件新闻投稿频道/com.TestFlightCN/31945

21.2K viewsApr 5 at 12:04

tg-me.com/TestFlightCN/31945

Create: 2025-04-05
Last Update: 2025-05-03 17:57:36

BY 科技圈🎗在花频道📮

Share with your friend now:
tg-me.com/TestFlightCN/31945

在花软件新闻投稿频道 Telegram | DID YOU KNOW?

However, analysts are positive on the stock now. “We have seen a huge downside movement in the stock due to the central electricity regulatory commission’s (CERC) order that seems to be negative from 2014-15 onwards but we cannot take a linear negative view on the stock and further downside movement on the stock is unlikely. Currently stock is underpriced. Investors can bet on it for a longer horizon," said Vivek Gupta, director research at CapitalVia Global Research.

Telegram is riding high, adding tens of million of users this year. Now the bill is coming due.Telegram is one of the few significant social-media challengers to Facebook Inc., FB -1.90% on a trajectory toward one billion users active each month by the end of 2022, up from roughly 550 million today.